A number of firms have modified their ratings and price targets on shares of Catabasis Pharmaceuticals (NASDAQ: CATB) recently:

  • 3/20/2017 – Catabasis Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $4.00 price target on the stock.
  • 3/18/2017 – Catabasis Pharmaceuticals was given a new $11.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 3/14/2017 – Catabasis Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $4.00 price target on the stock.
  • 3/2/2017 – Catabasis Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Catabasis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutics for treatment of inflammatory, immunological and metabolic diseases. Its product development pipeline includes CAT-1004, CAT-2000 series including CAT-2054 and CAT-2003, CAT-4001 as well as various programs which are in different clinical-stage. Catabasis Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. “
  • 2/6/2017 – Catabasis Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Catabasis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of therapeutics for treatment of inflammatory, immunological and metabolic diseases. Its product development pipeline includes CAT-1004, CAT-2000 series including CAT-2054 and CAT-2003, CAT-4001 as well as various programs which are in different clinical-stage. Catabasis Pharmaceuticals, Inc. is based in Cambridge, Massachusetts. “
  • 2/2/2017 – Catabasis Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $4.00 price target on the stock, down previously from $15.00.
  • 2/1/2017 – Catabasis Pharmaceuticals was downgraded by analysts at Cowen and Company from an “outperform” rating to a “market perform” rating. They now have a $4.00 price target on the stock.
  • 2/1/2017 – Catabasis Pharmaceuticals was downgraded by analysts at Citigroup Inc from a “buy” rating to a “neutral” rating.
  • 1/31/2017 – Catabasis Pharmaceuticals was given a new $11.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.

Catabasis Pharmaceuticals Inc (NASDAQ:CATB) opened at 1.45 on Tuesday. The stock’s 50 day moving average is $1.54 and its 200 day moving average is $3.55. The stock’s market capitalization is $27.05 million. Catabasis Pharmaceuticals Inc has a 12-month low of $1.08 and a 12-month high of $7.89.

Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

5 Day Chart for NASDAQ:CATB

Receive News & Ratings for Catabasis Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.